Thursday, July 9, 2026

pharma · Squamous Cell Carcinoma of Head and Neck · Breast Cancer · TVRD

Tvardi Therapeutics

Tvardi Therapeutics is a pharma organization headquartered in Houston, USA. It trades on NYSE under ticker TVRD. Primary therapeutic focus areas include Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Head and N

Houston, USA HQ
2017 Founded
20 Employees
Public company Type
TVRD · NYSE Ticker
Company details
Status
Public
HQ
Houston, USA
Founded
2017
Employees
20
Programs
6
Drugs
2
Patents
6
Clinical program

TTI-101

Phase 1 · small molecule · Breast Cancer

TTI-101 for Breast Cancer is a Phase 1 program (small_molecule) at Tvardi Therapeutics with 2 ClinicalTrials.gov record(s).

← All Tvardi Therapeutics projects Phase 1 small molecule completed

Internal code SM_CP2016-0842

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Tvardi Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Breast Cancer
Status
completed
Trials
2

Clinical trials